HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. said its core program, FP-001 LMIS (leuprolide mesylate injectable suspension) 25 mg, has shown positive phase III data, similar to those of its FP-001 LMIS 50 mg and marketed drugs of the same class.